Registry-listed formulations

vanoxerine · mesh:C043425

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 1 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)

Phase Distribution

Phase 1
1
50%
Phase 2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1

Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals

NCT00218049
completedphase_2

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT01691313

Clinical Trials (2)

Showing 2 of 2 trials
NCT00218049Phase 1

Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals

Terminated
NCT01691313Phase 2

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Completed

All 2 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
2

External References

ChEMBL
CHEMBL281594

Names & Codes

Research Codes

GBR 12909I 893